Baxter drug joins group of high-profile Alzheimer's failures
This article was originally published in Scrip
Baxter International said a therapy being tested for Alzheimer’s disease failed to meet its targets in a late-stage study, marking the latest high-profile clinical setback for treating the debilitating condition.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.